Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
This report elaborates on the current development of the PD-1 Inhibitor industry thoroughly based on the international market dynamics and China's market situation.
For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.
Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market.
Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.
By Player:
Sumitomo Dainippon Pharma
Tiziana Life Sciences
Pfizer
Merck
Novartis
AstraZeneca
Onxeo
Genentech (Roche)
By Type:
Other
Nivolumab
Pembrolizumab
Avelumab
Atezolizumab
Durvalumab
By Application:
Urothelial Carcinoma
Non-small Cell Lung Cancer (NSCLC)
Renal Cell Carcinoma
Other
Melanoma
Classical Hodgkin Lymphoma
By Research Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
Chapter 1 China PD-1 Inhibitor Market Overview 2018-2029
-
1.1 China PD-1 Inhibitor Industry Development Overview
-
1.2 China PD-1 Inhibitor Industry Development History
-
1.3 China PD-1 Inhibitor Industry Market Size (2018-2029)
-
1.4 China PD-1 Inhibitor Market Analysis by Type from Production Side
-
1.4.1 China PD-1 Inhibitor Production Volume, Production Value and Growth Rate of Other (2018-2029)
-
1.4.2 China PD-1 Inhibitor Production Volume, Production Value and Growth Rate of Nivolumab (2018-2029)
-
1.4.3 China PD-1 Inhibitor Production Volume, Production Value and Growth Rate of Pembrolizumab (2018-2029)
-
1.4.4 China PD-1 Inhibitor Production Volume, Production Value and Growth Rate of Avelumab (2018-2029)
-
1.4.5 China PD-1 Inhibitor Production Volume, Production Value and Growth Rate of Atezolizumab (2018-2029)
-
1.4.6 China PD-1 Inhibitor Production Volume, Production Value and Growth Rate of Durvalumab (2018-2029)
-
1.5 China PD-1 Inhibitor Market Analysis by Application from Consumption End
-
1.5.1 China PD-1 Inhibitor Sales Volume, Sales Value and Growth Rate of Urothelial Carcinoma (2018-2029)
-
1.5.2 China PD-1 Inhibitor Sales Volume, Sales Value and Growth Rate of Non-small Cell Lung Cancer (NSCLC) (2018-2029)
-
1.5.3 China PD-1 Inhibitor Sales Volume, Sales Value and Growth Rate of Renal Cell Carcinoma (2018-2029)
-
1.5.4 China PD-1 Inhibitor Sales Volume, Sales Value and Growth Rate of Other (2018-2029)
-
1.5.5 China PD-1 Inhibitor Sales Volume, Sales Value and Growth Rate of Melanoma (2018-2029)
-
1.5.6 China PD-1 Inhibitor Sales Volume, Sales Value and Growth Rate of Classical Hodgkin Lymphoma (2018-2029)
-
1.6 China PD-1 Inhibitor Market Analysis by Region
-
1.6.1 North China PD-1 Inhibitor Market Size and Growth Rate from 2018-2029
-
1.6.2 Central China PD-1 Inhibitor Market Size and Growth Rate from 2018-2029
-
1.6.3 South China PD-1 Inhibitor Market Size and Growth Rate from 2018-2029
-
1.6.4 East China PD-1 Inhibitor Market Size and Growth Rate from 2018-2029
-
1.6.5 Northeast China PD-1 Inhibitor Market Size and Growth Rate from 2018-2029
-
1.6.6 Southwest China PD-1 Inhibitor Market Size and Growth Rate from 2018-2029
-
1.6.7 Northwest China PD-1 Inhibitor Market Size and Growth Rate from 2018-2029
Chapter 2 China PD-1 Inhibitor Industry Development Environment
-
2.1 Industry Development Environment Analysis
-
2.1.1 Industry Technological Progress Analysis
-
2.1.2 Industrial Organizational Innovation Analysis
-
2.1.3 Changes in Social Habits
-
2.1.4 Alterations in Government Policies
-
2.1.5 Impact of Economic Globalization
-
2.2 Domestic and Foreign Industry Competition Analysis
-
2.2.1 Comparative Analysis on PD-1 Inhibitor Market Status and Competition at home and abroad in 2023
-
2.2.2 China PD-1 Inhibitor Market Status and Competition Analysis in 2023
-
2.2.3 China PD-1 Inhibitor Market Concentration Analysis in 2023
-
2.3 Problems and Countermeasures in the development of China PD-1 Inhibitor Industry
-
2.3.1 Industry Development Constraints
-
2.3.2 Industry Development Considerations
-
2.3.3 Suggestions on Industry Development Measures
-
2.3.4 Development Strategies for SMEs
-
2.4 Influence of COVID-19 Outbreak on PD-1 Inhibitor Industry Development
Chapter 3 PD-1 InhibitorIndustry Chain Analysis
-
3.1 PD-1 Inhibitor Industry Chain
-
3.2 PD-1 Inhibitor Upstream Industry Analysis
-
3.2.1 Upstream Industry Development Status
-
3.2.2 Upstream Industry Development Forecast
-
3.2.3 Impact of Upstream Industry on the PD-1 Inhibitor Market
-
3.3 PD-1 Inhibitor Downstream Industry Analysis
-
3.3.1 Downstream Industry Development Status
-
3.3.2 Downstream Industry Development Forecast
-
3.3.3 Impact of Downstream Industry on the PD-1 Inhibitor Market
Chapter 4 China PD-1 Inhibitor Market, by Type
-
4.1 China PD-1 Inhibitor Market Trend, by Type
-
4.2 Product Types of Major Suppliers
-
4.3 Competitive Landscape of Major Types
-
4.4 China PD-1 Inhibitor Total Production Volume and Growth Rate from Production Side
-
4.5 China PD-1 Inhibitor Production Volume and Growth Rate, by Type
-
4.5.1 China PD-1 Inhibitor Production Volume and Growth Rate of Other
-
4.5.2 China PD-1 Inhibitor Production Volume and Growth Rate of Nivolumab
-
4.5.3 China PD-1 Inhibitor Production Volume and Growth Rate of Pembrolizumab
-
4.5.4 China PD-1 Inhibitor Production Volume and Growth Rate of Avelumab
-
4.5.5 China PD-1 Inhibitor Production Volume and Growth Rate of Atezolizumab
-
4.5.6 China PD-1 Inhibitor Production Volume and Growth Rate of Durvalumab
Chapter 5 China PD-1 Inhibitor Market, by Application
-
5.1 Downstream Market Overview
-
5.2 Competitive Landscape of Major Applications
-
5.3 Market Potential Analysis, by Application
-
5.4 China PD-1 Inhibitor Total Market Size and Growth Rate from Consumption End
-
5.5 China PD-1 Inhibitor Market Size and Growth Rate, by Application
-
5.5.1 China PD-1 Inhibitor Market Size and Growth Rate of Urothelial Carcinoma
-
5.5.2 China PD-1 Inhibitor Market Size and Growth Rate of Non-small Cell Lung Cancer (NSCLC)
-
5.5.3 China PD-1 Inhibitor Market Size and Growth Rate of Renal Cell Carcinoma
-
5.5.4 China PD-1 Inhibitor Market Size and Growth Rate of Other
-
5.5.5 China PD-1 Inhibitor Market Size and Growth Rate of Melanoma
-
5.5.6 China PD-1 Inhibitor Market Size and Growth Rate of Classical Hodgkin Lymphoma
Chapter 6 China PD-1 Inhibitor Market, by Region
-
6.1 China PD-1 Inhibitor Production Volume and Production Value, by Region
-
6.2 China PD-1 Inhibitor Sales Volume and Sales Value, by Region
Chapter 7 North China PD-1 Inhibitor Market Analysis
-
7.1 North China PD-1 Inhibitor Market, by Type
-
7.2 North China PD-1 Inhibitor Market, by Application
Chapter 8 Central China PD-1 Inhibitor Market Analysis
-
8.1 Central China PD-1 Inhibitor Market, by Type
-
8.2 Central China PD-1 Inhibitor Market, by Application
Chapter 9 South China PD-1 Inhibitor Market Analysis
-
9.1 South China PD-1 Inhibitor Market, by Type
-
9.2 South China PD-1 Inhibitor Market, by Application
Chapter 10 East China PD-1 Inhibitor Market Analysis
-
10.1 East China PD-1 Inhibitor Market, by Type
-
10.2 East China PD-1 Inhibitor Market, by Application
Chapter 11 Northeast China PD-1 Inhibitor Market Analysis
-
11.1 Northeast China PD-1 Inhibitor Market, by Type
-
11.2 Northeast China PD-1 Inhibitor Market, by Application
Chapter 12 Southwest China PD-1 Inhibitor Market Analysis
-
12.1 Southwest China PD-1 Inhibitor Market, by Type
-
12.2 Southwest China PD-1 Inhibitor Market, by Application
Chapter 13 Northwest China PD-1 Inhibitor Market Analysis
-
13.1 Northwest China PD-1 Inhibitor Market, by Type
-
13.2 Northwest China PD-1 Inhibitor Market, by Application
Chapter 14 Company Profiles
-
14.1 Sumitomo Dainippon Pharma
-
14.1.1 Sumitomo Dainippon Pharma Company Profile
-
14.1.2 Sumitomo Dainippon Pharma PD-1 Inhibitor Market Performance
-
14.1.3 Product&Service Introduction
-
14.2 Tiziana Life Sciences
-
14.2.1 Tiziana Life Sciences Company Profile
-
14.2.2 Tiziana Life Sciences PD-1 Inhibitor Market Performance
-
14.2.3 Product&Service Introduction
-
14.3 Pfizer
-
14.3.1 Pfizer Company Profile
-
14.3.2 Pfizer PD-1 Inhibitor Market Performance
-
14.3.3 Product&Service Introduction
-
14.4 Merck
-
14.4.1 Merck Company Profile
-
14.4.2 Merck PD-1 Inhibitor Market Performance
-
14.4.3 Product&Service Introduction
-
14.5 Novartis
-
14.5.1 Novartis Company Profile
-
14.5.2 Novartis PD-1 Inhibitor Market Performance
-
14.5.3 Product&Service Introduction
-
14.6 AstraZeneca
-
14.6.1 AstraZeneca Company Profile
-
14.6.2 AstraZeneca PD-1 Inhibitor Market Performance
-
14.6.3 Product&Service Introduction
-
14.7 Onxeo
-
14.7.1 Onxeo Company Profile
-
14.7.2 Onxeo PD-1 Inhibitor Market Performance
-
14.7.3 Product&Service Introduction
-
14.8 Genentech (Roche)
-
14.8.1 Genentech (Roche) Company Profile
-
14.8.2 Genentech (Roche) PD-1 Inhibitor Market Performance
-
14.8.3 Product&Service Introduction
Chapter 15 Research Conclusions and Investment Suggestions
-
15.1 PD-1 Inhibitor Industry Research Conclusions
-
15.2 PD-1 Inhibitor Industry Investment Suggestions
-
15.2.1 Suggestions on Industry Development Strategy
-
15.2.2 Suggestions on Industry Investment Direction
-
15.2.3 Suggestions on Industry Investment Strategy
List of Tables and Figures
-
Figure China PD-1 Inhibitor Industry Market Size (2018-2029)
-
Figure China PD-1 Inhibitor Production Volume, Production Value and Growth Rate of Other (2018-2029)
-
Figure China PD-1 Inhibitor Production Volume, Production Value and Growth Rate of Nivolumab (2018-2029)
-
Figure China PD-1 Inhibitor Production Volume, Production Value and Growth Rate of Pembrolizumab (2018-2029)
-
Figure China PD-1 Inhibitor Production Volume, Production Value and Growth Rate of Avelumab (2018-2029)
-
Figure China PD-1 Inhibitor Production Volume, Production Value and Growth Rate of Atezolizumab (2018-2029)
-
Figure China PD-1 Inhibitor Production Volume, Production Value and Growth Rate of Durvalumab (2018-2029)
-
Figure China PD-1 Inhibitor Sales Volume, Sales Value and Growth Rate of Urothelial Carcinoma (2018-2029)
-
Figure China PD-1 Inhibitor Sales Volume, Sales Value and Growth Rate of Non-small Cell Lung Cancer (NSCLC) (2018-2029)
-
Figure China PD-1 Inhibitor Sales Volume, Sales Value and Growth Rate of Renal Cell Carcinoma (2018-2029)
-
Figure China PD-1 Inhibitor Sales Volume, Sales Value and Growth Rate of Other (2018-2029)
-
Figure China PD-1 Inhibitor Sales Volume, Sales Value and Growth Rate of Melanoma (2018-2029)
-
Figure China PD-1 Inhibitor Sales Volume, Sales Value and Growth Rate of Classical Hodgkin Lymphoma (2018-2029)
-
Figure North China PD-1 Inhibitor Market Size and Growth Rate from 2018-2029
-
Figure Central China PD-1 Inhibitor Market Size and Growth Rate from 2018-2029
-
Figure South China PD-1 Inhibitor Market Size and Growth Rate from 2018-2029
-
Figure East China PD-1 Inhibitor Market Size and Growth Rate from 2018-2029
-
Figure Northeast China PD-1 Inhibitor Market Size and Growth Rate from 2018-2029
-
Figure Southwest China PD-1 Inhibitor Market Size and Growth Rate from 2018-2029
-
Figure Northwest China PD-1 Inhibitor Market Size and Growth Rate from 2018-2029
-
Figure PD-1 Inhibitor Industry Chain
-
Table Product Types of Major Suppliers in 2023
-
Figure China PD-1 Inhibitor Market Share by Type in 2018
-
Figure China PD-1 Inhibitor Market Share by Type in 2023
-
Figure China PD-1 Inhibitor Total Production Volume and Growth Rate from Production Side (2018-2023)
-
Figure China PD-1 Inhibitor Production Volume and Growth Rate of Other (2018-2023)
-
Figure China PD-1 Inhibitor Production Volume and Growth Rate of Nivolumab (2018-2023)
-
Figure China PD-1 Inhibitor Production Volume and Growth Rate of Pembrolizumab (2018-2023)
-
Figure China PD-1 Inhibitor Production Volume and Growth Rate of Avelumab (2018-2023)
-
Figure China PD-1 Inhibitor Production Volume and Growth Rate of Atezolizumab (2018-2023)
-
Figure China PD-1 Inhibitor Production Volume and Growth Rate of Durvalumab (2018-2023)
-
Figure China PD-1 Inhibitor Market Share by Application in 2018
-
Figure China PD-1 Inhibitor Market Share by Application in 2023
-
Figure China PD-1 Inhibitor Total Market Size and Growth Rate from Consumption End
-
Figure China PD-1 Inhibitor Market Size and Growth Rate of Urothelial Carcinoma (2018-2023)
-
Figure China PD-1 Inhibitor Market Size and Growth Rate of Non-small Cell Lung Cancer (NSCLC) (2018-2023)
-
Figure China PD-1 Inhibitor Market Size and Growth Rate of Renal Cell Carcinoma (2018-2023)
-
Figure China PD-1 Inhibitor Market Size and Growth Rate of Other (2018-2023)
-
Figure China PD-1 Inhibitor Market Size and Growth Rate of Melanoma (2018-2023)
-
Figure China PD-1 Inhibitor Market Size and Growth Rate of Classical Hodgkin Lymphoma (2018-2023)
-
Table China PD-1 Inhibitor Production Volume by Region (2018-2023)
-
Table China PD-1 Inhibitor Production Volume Share by Region (2018-2023)
-
Figure China PD-1 Inhibitor Production Volume Share by Region (2018-2023)
-
Table China PD-1 Inhibitor Production Value by Region (2018-2023)
-
Table China PD-1 Inhibitor Production Value Share by Region (2018-2023)
-
Figure China PD-1 Inhibitor Production Value Share by Region (2018-2023)
-
Table China PD-1 Inhibitor Sales Volume by Region (2018-2023)
-
Table China PD-1 Inhibitor Sales Volume Share by Region (2018-2023)
-
Figure China PD-1 Inhibitor Sales Volume Share by Region (2018-2023)
-
Table China PD-1 Inhibitor Sales Value by Region (2018-2023)
-
Table China PD-1 Inhibitor Sales Value Share by Region (2018-2023)
-
Figure China PD-1 Inhibitor Sales Value Share by Region (2018-2023)
-
Table North China PD-1 Inhibitor Production Volume by Type (2018-2023)
-
Table North China PD-1 Inhibitor Production Volume Share by Type (2018-2023)
-
Figure North China PD-1 Inhibitor Production Volume Share by Type (2018-2023)
-
Table North China PD-1 Inhibitor Sales Volume by Application (2018-2023)
-
Table North China PD-1 Inhibitor Sales Volume Share by Application (2018-2023)
-
Figure North China PD-1 Inhibitor Sales Volume Share by Application (2018-2023)
-
Table Central China PD-1 Inhibitor Production Volume by Type (2018-2023)
-
Table Central China PD-1 Inhibitor Production Volume Share by Type (2018-2023)
-
Figure Central China PD-1 Inhibitor Production Volume Share by Type (2018-2023)
-
Table Central China PD-1 Inhibitor Sales Volume by Application (2018-2023)
-
Table Central China PD-1 Inhibitor Sales Volume Share by Application (2018-2023)
-
Figure Central China PD-1 Inhibitor Sales Volume Share by Application (2018-2023)
-
Table South China PD-1 Inhibitor Production Volume by Type (2018-2023)
-
Table South China PD-1 Inhibitor Production Volume Share by Type (2018-2023)
-
Figure South China PD-1 Inhibitor Production Volume Share by Type (2018-2023)
-
Table South China PD-1 Inhibitor Sales Volume by Application (2018-2023)
-
Table South China PD-1 Inhibitor Sales Volume Share by Application (2018-2023)
-
Figure South China PD-1 Inhibitor Sales Volume Share by Application (2018-2023)
-
Table East China PD-1 Inhibitor Production Volume by Type (2018-2023)
-
Table East China PD-1 Inhibitor Production Volume Share by Type (2018-2023)
-
Figure East China PD-1 Inhibitor Production Volume Share by Type (2018-2023)
-
Table East China PD-1 Inhibitor Sales Volume by Application (2018-2023)
-
Table East China PD-1 Inhibitor Sales Volume Share by Application (2018-2023)
-
Figure East China PD-1 Inhibitor Sales Volume Share by Application (2018-2023)
-
Table Northeast China PD-1 Inhibitor Production Volume by Type (2018-2023)
-
Table Northeast China PD-1 Inhibitor Production Volume Share by Type (2018-2023)
-
Figure Northeast China PD-1 Inhibitor Production Volume Share by Type (2018-2023)
-
Table Northeast China PD-1 Inhibitor Sales Volume by Application (2018-2023)
-
Table Northeast China PD-1 Inhibitor Sales Volume Share by Application (2018-2023)
-
Figure Northeast China PD-1 Inhibitor Sales Volume Share by Application (2018-2023)
-
Table Southwest China PD-1 Inhibitor Production Volume by Type (2018-2023)
-
Table Southwest China PD-1 Inhibitor Production Volume Share by Type (2018-2023)
-
Figure Southwest China PD-1 Inhibitor Production Volume Share by Type (2018-2023)
-
Table Southwest China PD-1 Inhibitor Sales Volume by Application (2018-2023)
-
Table Southwest China PD-1 Inhibitor Sales Volume Share by Application (2018-2023)
-
Figure Southwest China PD-1 Inhibitor Sales Volume Share by Application (2018-2023)
-
Table Northwest China PD-1 Inhibitor Production Volume by Type (2018-2023)
-
Table Northwest China PD-1 Inhibitor Production Volume Share by Type (2018-2023)
-
Figure Northwest China PD-1 Inhibitor Production Volume Share by Type (2018-2023)
-
Table Northwest China PD-1 Inhibitor Sales Volume by Application (2018-2023)
-
Table Northwest China PD-1 Inhibitor Sales Volume Share by Application (2018-2023)
-
Figure Northwest China PD-1 Inhibitor Sales Volume Share by Application (2018-2023)
-
Table Sumitomo Dainippon Pharma Company Profile
-
Table Sumitomo Dainippon Pharma PD-1 Inhibitor Revenue, Price and Gross (2018-2023)
-
Table Tiziana Life Sciences Company Profile
-
Table Tiziana Life Sciences PD-1 Inhibitor Revenue, Price and Gross (2018-2023)
-
Table Pfizer Company Profile
-
Table Pfizer PD-1 Inhibitor Revenue, Price and Gross (2018-2023)
-
Table Merck Company Profile
-
Table Merck PD-1 Inhibitor Revenue, Price and Gross (2018-2023)
-
Table Novartis Company Profile
-
Table Novartis PD-1 Inhibitor Revenue, Price and Gross (2018-2023)
-
Table AstraZeneca Company Profile
-
Table AstraZeneca PD-1 Inhibitor Revenue, Price and Gross (2018-2023)
-
Table Onxeo Company Profile
-
Table Onxeo PD-1 Inhibitor Revenue, Price and Gross (2018-2023)
-
Table Genentech (Roche) Company Profile
-
Table Genentech (Roche) PD-1 Inhibitor Revenue, Price and Gross (2018-2023)
-
